Aktienanalyse zu Treace Medical Concepts, Inc (TMCI)TMCITreace Medical Concepts, Inc

Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Treace Medical Concepts Inc (TMCI) is a good buy right now at a current price of $4.65, especially considering its recent price momentum with a 5-day change of +7.14% and a year-to-date change of +86.00%. The stock's RSI is at 54.404, indicating it is neither overbought nor oversold, which suggests potential for further upside. However, the main risk is the negative earnings trend, with a reported EPS of -0.24 for Q2 2026, which reflects ongoing losses.